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Curability of advanced breast cancer, either locally advanced or
metastatic, remains poor. With hormonal treatment and systemic
polychemotherapy, relapse-free survival (RFS) is 35% and overall
survival (OS) is 40% at 5 years for stage IIIB patients. For stage
IV patients, OS remain below 20% at 5 years (Flamm Honig,
1996). Several attempts have been made to further improve
relapse-free, progression-free (PFS) and overall survival in both
locally advanced and metastatic breast cancer, based on preclinical
and biological studies. A linear dose–response relationship has
been demonstrated particularly for alkylating agents which remain
among the most active drugs for breast cancer (Skipper et al,
1964). Many authors stressed the importance of cell repopulation
in the resistance of cancer to chemotherapy. Differences in the cell
death and repopulation curves (i.e. non-exponential versus expo-
nential) have led to the concept of timing and schedule as impor-
tant parameters for the efficacy of cytotoxic agents. The
shortening of the interval between the courses of chemotherapy
might therefore be at least as beneficial as the dose increase of the
same agents (reviewed in Gilewski and Norton, 1996). The
increased dose intensity or dose density of combination
chemotherapy regimens may be achieved by either increasing the
doses of the drugs, or shortening the intervals between courses, or
both. 
However, increasing the doses of cytotoxic agents was limited
by high haematological and infectious morbidity and mortality.
After 1990, haematologic support with haematopoietic growth
factors (G-CSF and GM-CSF) and blood cells progenitors derived
from the bone marrow (ABMT) or from peripheral blood (PBSC)
became widely available to circumvent the dose-limiting haemato-
logical toxicity and infectious complications. Many studies of
high-dose chemotherapy (HDC) with G-CSF and ABMT/PBSC
have been published, including studies dealing with HDC multi-
cycle regimens (Rodenhuis et al, 1996; Vahdat and Antman,
1997), and 3 randomized studies (Peters et al, 1996; Lotz et al,
1999; Stadtmauer et al, 2000). Most of these regimens included
only alkylating agents (Peters et al, 1996; Rodenhuis et al, 1996;
Antman et al, 1997; Vahdat and Antman, 1997; Stadtmauer et al,
2000), only 3% of them including mitoxantrone in the condi-
tioning combination (Antman et al, 1997; Vahdat and Antman,
1997; Lotz et al, 1999). A fourth randomized study had been
published earlier (Bezwoda et al, 1995), but an international audit
has demonstrated that ‘the multiple publications of this study (...)
do not report verifiable data’ (Weiss et al, 2001). The data from
this study will not be furthermore commented in the paper. 
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Summary The aim of this study was to evaluate the feasibility of a high-dose intensity and high-dose density multicycle epirubicin and
cyclophosphamide regimen with peripheral blood stem cells (PBSC) and haematopoietic growth factor (G-CSF) support in advanced breast
cancer patients. From August 1994 to September 1999, 56 breast cancer patients (8 stage IIIB and 48 stage IV) received 205 courses of
cyclophosphamide 3 g m–2 and epirubicin 100 mg m–2 every 14 days. G-CSF 5 µ g kg–1 day–1 was administered from day 3 to neutrophil
recovery. 4 courses were planned. PBSC were collected after course 1, and reinfused after courses 3 and 4, with ≥ 2 × 106 CD34+ PBSC kg–1
required for each reinfusion. 48 patients (86%) received all 4 planned courses. Early withdrawal was consecutive to infectious complications
(n = 4), severe asthenia (n = 3), haemorrhagic cystitis (n = 1). A median number of 10.8 × 106 CD34+ PBSC kg–1 (range, 3–80) was harvested
with 1 or 2 apheresis in 48 patients (94%). Median relative dose intensity was 91.3% (range, 72–102%). Grade 4 neutrophil toxicity was
observed in 100% of patients. Febrile neutropenia was observed in 40% of courses (median duration 2 days). Red blood cells and platelets
had to be transfused in 54% and 27% of courses, respectively. There were no toxic deaths. Objective response rate was 69% in stage IV
patients (31/45 evaluable pts), with a 16% complete response rate. Their median progression-free and overall survivals were 22.5 and 37
months, respectively. This epirubicine-containing high-dose regimen appeared feasible, albeit with high toxicity. Time-related progression
parameters exceed commonly reported ones. Controlled studies of upfront sequential high-dose chemotherapy are still needed to evaluate its
real benefit. © 2001 Cancer Research Campaign 
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Although anthracyclines are the reference agents in advanced
breast cancer and a clinical dose–response relationship has also
been demonstrated in advanced breast cancer with epirubicin
(Bastholt et al, 1996), no regimen had doxorubicin or epirubicin.
In 1986 we began an open phase II trial of an accelerated protocol
for stage IIIB–IV patients, associating epirubicin 75 mg m–2 and
cyclophosphamide 1200 mg m–2 every 2 weeks, given without any
haematopoietic support for 6 consecutive courses. The patients
were to be retreated at day 14 whatever the leukocyte count in the
absence of febrile neutropenia. This induction protocol was to be
followed by 6 months of conventional maintenance combination
chemotherapy. Results have already been reported, confirming its
feasibility, and underscoring its efficacy in terms of PFS and OS
(Culine et al, 1993; Extra et al, 1995; Cottu et al, 1999). Other
investigators have proposed a similar approach including
haematopoietic growth factor support, which did not significantly
improve the delivered dose intensity nor the clinical results
(Piccart et al, 1995; Lalisang et al, 1997). 
Since most very high-dose studies have been limited to 
one or two treatment courses which usually did not include 
anthracyclines, and based on our previous results of a dose 
dense epirubicin–cyclophosphamide combination, we devel–
oped a further incrementalistic anthracycline-containing
chemotherapy regimen, consisting of 4 courses of high-dose 2-
weekly chemotherapy regimen including epirubicin and
cyclophosphamide, supported by haematopoietic growth factors
and PBSC, as induction therapy for stage IIIB–IV breast cancer
patients, followed by conventional maintenance chemotherapy.
The main objectives were to assess the feasibility of this approach,
to determine acute haematological and extra-haematological toxi-
city, and long-term side-effects, and to evaluate the potential effi-
cacy, focusing on the PFS and OS results. We report here the
results of our experience in 56 patients. 
PATIENTS AND METHODS 
Patients 
Women with histologically proven breast adenocarcinoma were
included. Stage IV and IIIB (with T4d tumours) patients, with
evaluable and/or measurable disease, were to be included. Other
inclusion criteria were: age 18–55, PS 0–1, adequate left ventric-
ular ejection fraction (LVEF) as assessed by gated radionuclide
scan (i.e. ≥ 50%), normal liver function (i.e. transaminases ≤ 1.5
N, alkaline phosphatases ≤ 1.5 N, total bilirubin ≤ N), normal renal
function (serum creatinine clearance > 80 ml min–1), normal blood
count before the first course. The possibility of close follow-up
was a compulsory accrual clause. Metastatic patients who had
received adjuvant chemotherapy were not excluded if the cumu-
lated doses of epirubicin and/or doxorubicin were under 400 mg
m–2 or 300 mg m–2, respectively. Extensive disease evaluation was
performed, including complete physical examination, mammo-
grams, isotopic bone scan, abdominal ultrasound exploration,
bone marrow biopsy, serum tumour markers. Chest and abdominal
computerized tomography (CT scan) were done when indicated.
Exclusion criteria were: age over 55, PS ≥ 2, metastatic bone
marrow, inadequate liver, renal or cardiac function (LVEF < 50%),
elevation of serum tumour marker(s) as sole evidence of disease,
previous chemotherapy for metastatic or advanced disease, or
history of any other malignancy. All patients had given informed
consent. 
Chemotherapy 
Chemotherapy consisted of epirubicin 100 mg m–2 day 1 in a short
i.v. infusion, and cyclophosphamide 1500 mg m–2 day 1 and day 2
(i.e. 3000 mg m–2 per course) with equidose uromitexan in 1 hour
i.v. infusion. Patients were hospitalised in the afternoon of day 1
and released in the morning of day 3. They received 4 litres of
isotonic saline solution/24 h as continuous intravenous infusion
for 2 days, along with corticosteroids and serotonin antagonists as
antiemetic medication. Furosemide 20 mg i.v. was administered if
the 6 hours diuresis was under 800 ml. The treatment was to be
resumed every 14 days, whatever the absolute neutrophil count. If
the patient presented with febrile neutropenia, the treatment was
resumed after 24 h of apyrexia. The treatment was delayed until
recovery in case of persistent thrombocytopenia inferior to 30 000
mm–3, transaminases elevation above 2.5 × N, or serum creatinine
clearance under 80 ml min–1. The patients were withdrawn from
the study if any of the following complications occurred: persis-
tent (> 7 days) febrile neutropenia, grade 4 infection, platelets <
30.109 1–1 at day 21, grade 3–4 non-haematological complication
persistent at day 21. Platelets and red blood cells were transfused
in an ambulatory setting if under 20.109 1–1, and haemoglobin
under 8 g dl–1, respectively, or as clinically indicated. 4 courses
were planned before re-evaluation. Evaluation of response was
assessed according to WHO criteria. For patients who had stage
IIIB or stage IV at presentation breast cancer, local therapy
including surgery and radiation therapy was performed as indi-
cated. Pathological response was assessed separately for the breast
and the axillary lymph nodes, and was divided into complete (no
viable tumour cells), partial (post chemotherapeutic changes with
persistent viable tumour cells) and no response, and node-positive
or node-negative, respectively. 
The dose intensity (DI) was computed for every patient who 
had completed the 4 courses. No dose reduction was allowed, 
and the treatment was reconducted on the 14th day whatever 
the neutrophil count, except if the patient presented with any of the
complications previously described. Thus, only the number of
days between day 1 of course 1 (Date C1) and day 1 of course 4
(Date C4) was used in the calculation with the following formula:
DI = [Date C4 – Date C1] / 42, where 42 represents the minimal
duration between day 1 of course 1 and day 1 of course 4 (Shapiro
et al, 1997). 
Maintenance chemotherapy consisted of a 6 months outpatient
alternative regimen including CMF (months 1–4), a combination
of 5-fluorouracil, methotrexate and vincristine (months 2–5), and
5-fluorouracil/adriamycin/cyclophosphamide (FAC) (months 3–6).
Tamoxifen was added to patients whose primary tumour expressed
estrogen receptors, provided they had not received and/or failed
adjuvant hormonal therapy. Patients with progressive disease
during or after the completion of the study regimen were given
vinorelbine- or, more recently, docetaxel-based regimens. Patients
with CNS disease were not given radiation therapy, unless they
evidenced progressive and/or symptomatic disease. 
Cellular therapy 
Recombinant human granulocyte-colony stimulating factor (G-
CSF) at a daily dose of 5 µ g kg–1 given subcutaneously was used
from day 3 until neutrophil recovery (i.e. > 1000 mm–3) or until
day –2 of the following course, for the 4 courses. Peripheral blood
stem cells (PBSC) were mobilized after the first course by the1242 PH Cottu et al 
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combination of chemotherapy and G-CSF. Patients had complete
blood count measured every other day, and cell apheresis began
during the rebound recovery period. Collections were performed
in order to obtain a total of 4 × 106 CD34+ PBSC kg–1, which was
considered as necessary for an appropriate engraftment, i.e. 2 × 106
CD34+ PBSC kg–1 for course 3 and 4. The apheresis was repeated
until the scheduled 4 × 106 CD34+ PBSC kg–1 were collected, and
if necessary was repeated after course 2. The apheresis was
delayed if the patient had febrile neutropenia. For each apheresis, a
median of 10 l of blood were processed at a flow rate of 40–60 ml
min–1. Acid-citrate-dextrose (ACD-A) was used as the inlet AC
ratio. The quantity of progenitor cells was assessed by numeration
of CD34+ cells. CD34+ cells count assay was performed after
staining with HPCA2 (a monoclonal antibody against CD34+ anti-
gene). Fluorocytometry was performed on a fluorescent automatic
cell sorter. 50 000 events were acquired. The absolute number of
CD34+ cells was derived by multiplying the percentage of CD34+
cells and the absolute number of mononucleated cells. Apheresis
collections were cryopreserved in a minimum of 4 bags. The cells
were volume adjusted to a final concentration inferior to 1.5 × 108
WBC ml–1. The final product containing 10% DMSO (dimethlyl
sulfoxide) in autologous plasma was frozen according to standard
methods and stored in liquid nitrogen. Before reinfusion, cells
were thawed in the stem cell laboratory, and suspended in an
albumin 4% and sodium chloride buffer. A cell count, a viability
assay and a CD34+ assay were performed. Reinjection was done
over 30–60 minutes in the clinical unit. 
Epithelial cell contamination of the grafts was determined
and will be described in a separate report (Dal Cortivo et al,
2001). 
Toxicity monitoring 
The treatment was designed as an outpatient programme. All toxi-
cities were graded according to the WHO criteria. Close clinical
follow-up was done, including daily telephone contact with the
patient when necessary. Complete blood count and biochemistry
tests were monitored 2 or 3 times a week. Every patient received
oral antibiotherapy with cefixime (200 mg twice daily) as soon as
fever was higher than 38˚C. If fever persisted more than 24 h, or if
overt signs of infections appeared, the patient was hospitalized for
evaluation and intravenous broad-spectrum double antibiotherapy.
Patients were also hospitalized if they presented persistent grade 3
extra-haematological toxicity (emesis, liver, renal and cardiac
toxicity). Preventive treatment of mucositis consisted in multiple
daily mouth washes with a solution of amphotericine B, chlorhex-
idine and 1.4% sodium bicarbonate. Cardiac toxicity was clinically
evaluated after each course, and with a LVEF evaluation at the end
of the 4 high-dose courses and of maintenance therapy. 
Objectives 
The primary aim of the study was to assess the feasibility of 
a multi-cycle high-dose-intensity and dose-density regimen
including epirubicin. The feasibility criteria we had pre-defined as
acceptable were: appropriate leukapheresis for 2 engraftments, i.e.
more than 4 × 106 CD34+ PBSC kg–1; relative dose intensity
greater than 80% in more than 80% of patients; treatment-related
mortality inferior to 5%. Dose-limiting toxicities are described
above. The secondary aim was the assessment of the efficacy of
the treatment. The 4 courses were to be administered in at least
80% of the patients, and we expected less than 10% of patients
with progressive disease at the end of high-dose treatment. 
Statistical methods 
Descriptive statistics are reported as percentages and medians
(Snedecor and Cochran, 1989). Overall survival and PFS were
defined as the time from the day of the first course to death,
disease relapse or disease progression, respectively. Progression of
disease was defined as any progression of known metastatic site
according to WHO criteria, or of emergence of a new site,
including contralateral breast. Survival curves were constructed
with the Kaplan and Meier product-limit method (Kaplan and
Meier, 1958). Univariate analysis of prognostic factors for OS 
and PFS was conducted using the log-rank test (Snedecor and
Cochran, 1989). Data acquisition for PFS and OS was done until
January 31st, 2000. 
RESULTS 
Population 
From August 1st, 1994 to September 1st, 1999, 56 patients were
entered in the study. All patients but 2 were treated at Hospital
Saint-Louis. Details of presentation are shown in Table 1. Median
age was 43.4 (range, 23.5–57). The population included 8 patients
with stage IIIB (T4d) carcinoma, 27 patients with stage IV at
presentation, and 21 relapsing metastatic patients. This accounted
for about 15% of all new stage IV patients who were referred to
our centre in the same time span. 13 relapsing metastatic patients
had received previous adjuvant chemotherapy, 8 of them with
anthracyclines. Median disease-free interval for this subset of
patients was 37 months (range, 13–98). A high proportion (67%)
had 2 or more involved sites, and nearly the same proportion
(65%) had at least one visceral metastatic site. Main metastatic
sites for all stage IV patients were liver (40%), lymph nodes
(40%), bone (38%), and lung (19%). 13 patients with stage IV
disease at presentation and 6 stage IIIB patients underwent mastec-
tomy and axillary dissection after the induction chemotherapy, and
were evaluated for pathological response. 
Toxicity and feasibility 
All patients, receiving a total of 205 treatment courses, were evalu-
able for feasibility and toxicity (Tables 2 and 3). Leukapheresis
with G-CSF support was performed as planned (Table 2). The
median day for collection was day 11 after course 1. One leuka-
pheresis collection was sufficient in 40 patients (72%), and only 3
patients (5%) had 3 or more collections. The median number of
collected CD34+ PBSC was 10.8 × 106 kg–1 (range 3–80), and 54
patients (96%) had more than 4 × 106 CD34+ PBSC kg–1. The rela-
tive dose-intensity was computed for the 48 patients who had
completed the 4 courses. The resulting median relative dose-
intensity was 91.3% (range 72–102). It is noteworthy that 80% and
94% of patients had a dose-intensity greater than 90% and 80%,
respectively. Conventional maintenance chemotherapy, radiation
therapy when indicated, and second-line therapy were feasible
without any unusual toxicity (data not shown). 
No treatment-related death has been recorded. The treatment
had to be interrupted before completion of the 4 courses in 8
patients (14%): 1 patient with haemorrhagic cystitis after course 3,Multicycle high-dose chemotherapy for advanced breast cancer 1243
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3 patients with persistent grade 3 asthenia after courses 2 (2
patients) and 3 (1 patient), and 4 patients with grade 3–4 infection
after courses 1 (3 patients) and 3 (1 patient). One of the latter
patients presented grade 3 oesophagitis and non-metastatic bowel
invagination which required a 30 cm bowel surgical excision.
Another patient had iterative febrile neutropenia episodes lasting
longer than 7 days. The last 2 patients presented subcutaneous
infectious cellulitis (Staphylococcus aureus), one of whom
required surgical excision. Details of toxicity by course are given
in Table 3. Briefly, grade 4 neutropenia was observed after 90% of
courses and in 100% of patients. Median duration of grade 4
neutropenia was 4 days (range, 2–11 days). Febrile neutropenia
requiring rehospitalisation was observed in 79 courses (39%),
with a median duration of 2 days. Only 13 patients (23%) did not
experience febrile neutropenia. Red blood cells had to be trans-
fused in 104 courses (51%) and in 49 patients (88%). Platelets
were transfused in 55 courses (27%), and in 32 patients (57%).
Median duration of grade 4 thrombopenia was 3, 2, 4 and 3 days
after courses 1, 2, 3 and 4, respectively. No significant change in
the LVEF has been observed, neither after induction, nor at the end
of maintenance therapy. Extra-haematological toxicity is shown in
Table 3. No grade 3 liver or renal toxicity was recorded. An on-
treatment decrease in the performance status was observed in 18
patients (32%), 3 of whom were withdrawn from the study. An
improvement was observed in 5 patients (9%). 14 patients (25%)
did not require rehospitalisation. 
Response and survival 
45 stage IV patients who had received at least 2 courses were
considered as evaluable for response. Clinical overall response
rate was 69% (95% CI: 55.5–82.5). Complete response rate was
16% (95% CI: 5.3–26.7). Intent-to-treat analysis for the 48
metastatic patients showed an overall response rate of 64.5% (95%
Table 1 Population characteristics (n = 56) 
Median Range 
Age at inclusion (years) 43.4 23.5–57 
Disease-free interval (months)a 37 13–98 
n%
Stage at inclusion IIIB (T4d) 8 14 
IV (presentation) 27 48 
IV (relapse) 21 38 
WHO performance status 0 39 70 
1 13 23 
24 7  
Menopausal status pre 47 84 
post 9 16 
Adjuvant chemotherapya With anthracyclines 8 38 
Without anthracyclines 5 24 
None 8 38 
Metastatic sitesb Liver 19 40 
Lymph nodes 19 40 
Bone 18 38 
Lung 9 19 
Pleura 3 6 
CNSc 36  
Skin 1 2 
Otherd 36  
Number of site(s)b 1 16 33 
≥ 2 32 67 
Number of viscera(e)b 0 17 35 
≥ 1 31 65 
aRefers to 21 patients who relapsed; brefers to 48 stage IV patients; cCNS: central nervous system.
Includes brain, epidural and meningeal metastases; d1 ovary and 2 peritoneal metastases. 
Table 2 Feasibility results (n = 56) 
n %
Number of courses 4 48 86
34 7
21 2
13 5
Number of leukapheresis 1 40 72
sessions 2 13 23
>2 3 5
Leukapheresis delay
Median (days) 11
Range 10–15
CD34+ 
Median (× 106/kg) 10.8
Range 3–80
≥ 4 × 106/kg 54 96
Dose intensitya
Median (%) 91.3
Range 72–102
≥ 80% 45 94
aEvaluated on the 48 patients who completed the 4 courses. CI: 51–78) with a 14.5% complete response rate of 14.5% (95%
CI: 4.5–24.5). Response rate according to metastatic site is shown
in Table 4. Only 2 patients (4%) experienced outright progression
at the end of the study regimen. Out of 6 evaluable inflammatory
breast cancer patients, 5 presented clinical objective response.
Overall response rate for the 56 patients was 64.3% (95% CI:
51.8–76.8). Pathological response was assessed in breast and in
axillary lymph nodes for the patients who underwent radical
mastectomy and axillary lymph nodes dissection after induction
chemotherapy. Breast pathological response was assessable in 19
patients (13 metastatic and 6 inflammatory). Complete response
was observed in 2 patients (11%) and partial response in 4 patients
(21%). 3 complete responses in axillary lymph node dissections
(17%) were observed among 18 evaluable patients. 
Median follow-up was 26 months for stage IV patients (range:
2–64). Survivals were computed from the first day of the first
course. Intent-to-treat median progression-free survival for stage
IV patients was 22.5 months. Median OS for stage IV patients was
37 months. Median OS for the 56 patients was 39 months (Figure
1). Median OS for stage IV patients with visceral metastases was
27 months (26 months in the 19 pts with liver metastases), and 48
months for patients with non-visceral metastases (P = 0.04).
Median PFS was, respectively, 20 months and 42 months (P =
0.04). As of January 31st, 2000, 3 stage IIIB patients had
progressed at 4, 5 and 28 months. The 5 other patients are disease-
free at 27+, 30+, 39+, 41+ and 43+ months. 
1244 PH Cottu et al 
British Journal of Cancer (2001) 85(9), 1240–1246 © 2001 Cancer Research Campaign
Table 3 Toxicity by course 
C1 (n = 56) C2 (n = 53) C3 (n = 52) C4 (n = 48) 
Neutrophils 
Grade 4 (%) 95 89 89 88 
Median duration (days) 4 4 6 5 
Range 2–81 –92 –11 2–10 
Fever 
% 30 28 30 37 
Median duration (days) 2 2 2 2 
Range 1–61 –61 –91 –13 
Hospitalization 
% 29 35 40 53 
Median duration (days) 3 4 3 4 
Range 1–22 1–71 –14 1–8 
Red blood cell transfusion 
% 22 60 74 60 
Median units 2 2 2 2 
Range 2–42 –42 –52 –4 
Platelets transfusion 
% 4 25 37 47 
Median units 9 6 6 6 
Range 6–12 6–48 6–48 6–36 
Nausea – vomiting 
Grade 2–3 (%) 37 42 32 19 
Grade 4 (%) 0 0 2 2 
Mucositis 
Grade 2–3 (%) 8 17 19 14 
Grade 4 (%) 2 0 2 0 
Liver toxicity 
Grade 1–2 (%) 33 19 17 19 
Grade 3 (%) 0 0 0 0 
Table 4 Response rate in the 48 stage IV patients 
n %
Complete response 7 14.5 
Partial response 24 50 
Overall response 31 64.5 
Stable disease 12 25 
Progressive disease 2
Objective response by site Liver 16 84 
Lymph nodes 16 84 
Pleura 2 67
Lung 5 56 
CNS 2 67
Figure 1 Overall and progression-free survival in the 56 patients 
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DISCUSSION 
On the basis of so far 3 reported randomized studies (Peters et al,
1996; Lotz et al, 1999; Stadtmauer et al, 2000), the value and
feasibility of HDC in metastatic breast cancer has been extensively
and critically reviewed (Antman, 1999; Crown et al, 1999;
Gradishar, 1999; Hortobagyi, 1999; Livingston and Crowley,
1999; MacNeil and Eisenhauer, 1999). The negative PBT-1 trial
(Stadtmauer et al, 2000), which included the largest number of
patients, has been widely commented: from 553 patients initially
included in the study, only 199 (of whom only 45 CR patients)
were amenable to randomization. The imbalance between the
prognostic factors of the 2 arms, favouring the control arm, has
also been questioned (Antman, 1999), as well as the concern about
the standard arm of continuous CMF (MacNeil and Eisenhauer,
1999). The trial thus suffered a spectacular attrition, and lost much
statistical power (Gradishar, 1999; Hortobagyi, 1999; Livingston
and Crowley, 1999). The two other studies (Lotz et al, 1999; Peters
et al, 1996) showed either significant differences or a trend for an
advantage for HDC. One of them included mitoxantrone, an
anthracyclin derivative, in the high-dose regimen, but with few
patients (Lotz et al, 1999), and one proposed upfront high-dose
chemotherapy in the experimental arm (Peters et al, 1996). 
The conditioning regimen of these studies varied in types of
drugs, doses and haematopoietic support. The optimal regimen
and schedule of HDC remains thus a striking question deserving
well designed trials, as underscored by all editorialists (Antman,
1999; Crown et al, 1999; Hortobagyi, 1999; Livingston and
Crowley, 1999; MacNeil and Eisenhauer, 1999). Another issue is
the determination of the characteristics of the patients likely to
benefit from HDC, with selection of patients for HDC trials being
another major problem. A review of 1581 metastatic patients
treated at the M.D Anderson Cancer Center with doxorubicin-
based regimens has shown that patients who presented conven-
tional eligibility criteria for HDC trials (younger age, performance
status ≤ 2, chemosensitivity) also had the best prognosis, with
median OS and PFS of 30 and 16 months respectively (Rahman
et al, 1997). These results had been shown after stratification
according to previously described prognostic factors (Ayash et al,
1995) and appear to be in the same range as the best results of
HDC trials. It is of note that extent of disease (number of
metastatic site and visceral involvement) did not differ between
HDC candidates and non-candidates, and was not included in the
prognostic analyses. Adverse prognostic factors for patients
entering HDC trials include previous adjuvant chemotherapy, liver
metastases, extensive metastatic disease and chemoresistant
disease (Ayash et al, 1995; Rizzieri et al, 1999; Rowlings et al,
1999). 
The present study tried to circumvent some of the factors
limiting the interpretation of the presently available HDC trials for
metastatic breast cancer. We first established the feasibility of a
multicycle, epirubicin-containing, high-dose regimen and the
criteria we had set were all met. Leukapheresis was efficient, as
more than 4 × 106 kg–1 CD34+ PBSC were collected in 54 patients
(96%, objective: 80%), and 1 or 2 leukapheresis sessions were
sufficient in 53 patients (94%). The dose-intensity was greater
than 80% in 45 out of the 48 patients (94%) who received the 4
courses (objective: 80%). 8 patients (16%) were withdrawn from
the study because of toxicity, though no toxicity-related death was
observed. 4 of these 8 patients had severe infectious complica-
tions, 3 had profound asthenia, and 1 haemorrhagic cystitis. No
long-term side effect was recorded; there was no cardiac function
deterioration, nor clinical cardiotoxicity detected. Most important,
surgery, radiation therapy, maintenance and second-line
chemotherapies were administered without unusual toxicity. The
patients who were included in the study presented many adverse
prognostic factors (Table 1), and were not preselected by the
chemosensitivity of their disease. Objective response was conserv-
atively assessed with a rate of 69% (intent to treat: 64.5%), and a
complete response rate of 16% (intent to treat: 14.5%). These
results have to be compared to those obtained with standard-dose
chemotherapy (reviewed in Flamm Honig, 1996). More recent
drugs have also been included in combination therapies, yielding
very promising results that may compare favourably with high-
dose chemotherapy (Dieras et al, 1996; Dieras, 1998). It is also of
note that escalating the dose of cyclophosphamide has not been
beneficial in the adjuvant setting (Fisher et al, 1997, 1999).
However, we report here a median overall survival (37 months)
and median progression-free survival (22.5 months) that are in the
high end of reported data for patients undergoing high-dose
chemotherapy as consolidation, with similar follow-up (Peters
et al, 1996; Antman et al, 1997; Lotz et al, 1999; Rowlings et al,
1999; Stadtmauer et al, 2000). Moreover, only 53% and 25% of
the ABMTR patients had visceral (32% liver) and extensive
disease, respectively (Rowlings et al, 1999), compared to 65% and
67% in the present study, respectively. The choice of epirubicin
over doxorubicin has contributed to the feasibility of our approach.
Its higher clearance, resulting from glucuronidation (Coukell and
Faulds, 1997), is probably at the root of its briefer haematotoxicity,
and has allowed the dose-intense, repetitive regimen we report
here. 
The reappraisal of HDC in metastatic breast cancer patients,
combined with the encouraging results of the present study which
included young patients with very poor prognosis, gives important
clues to the potential role of HDC in metastatic breast cancer
patients, yet to be explored for an eventual therapeutic contribu-
tion. High-dose chemotherapy with haematopoietic support should
be administered early, in a multicycle outpatient programme, and
should be epirubicine based. Several questions remain open, such
as the eventual role of taxanes in HDC protocols, even if a
dose–response effect has not been clearly demonstrated for this
family of cytotoxic agents (Hryniuk et al, 1998), and the role of
newly available therapies such as anti Her2/neu antibodies. Large
clinically relevant and well designed cooperative randomized
trials addressing these different issues are still awaited. 
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